Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.
Follow VRTX
Vertex Pharmaceuticals Incorporated (VRTX) Net income
Vertex Pharmaceuticals Incorporated's net income for fiscal 2025 was $4.0B, compared with −$535.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.4B. Over the past ten years it has ranged from −$588.2M (fiscal 2015) to $4.0B (fiscal 2025) — the current reading is the highest in ten years. Vertex Pharmaceuticals Incorporated ranks 1st of 612 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $4.0B | — |
| FY2024 | −$535.6M | — |
| FY2023 | $3.6B | 8.96% |
| FY2022 | $3.3B | 41.84% |
| FY2021 | $2.3B | (13.63%) |
| FY2020 | $2.7B | 130.43% |
| FY2019 | $1.2B | (43.62%) |
| FY2018 | $2.1B | 2,177.63% |
| FY2017 | $91.6M | — |
| FY2016 | −$84.0M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $1.1B | 6.63% |
| Mar 2026 | $1.0B | (13.41%) |
| Dec 2025 | $1.2B | 9.99% |
| Sep 2025 | $1.1B | 4.84% |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $4.4B |
| REGN Regeneron Pharmaceuticals, Inc. compare | $4.3B |
| ARGX argenex SE compare | $1.6B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $774.7M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $655.7M |
| ROIV Roivant Sciences Ltd. compare | −$414.6M |
| RVMD Revolution Medicines, Inc. compare | −$1.8B |
| MRNA Moderna, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on VRTX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement